Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lazertinib
Related studies linked through entity extraction aliases.
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Lazertinib (JNJ-73841937) in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1